Evidence map›Paper›PMID 42159954›Full record

ArticleAdvances in therapy2026

Moderate and Severe Exacerbations and Healthcare Resource Utilization in Chinese Patients with COPD on Triple Therapy: A Retrospective Database Study.

Ke Huang, Yanan Cui, Tingting Huang, Xiaoning He, Kailing Wang, Dan Shen, Yingrui Xu, Ting Yang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advances in therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Ke HuangDepartment of Pulmonary and Critical Care Medicine, National Center for Respiratory Medicine, State Key Laboratory of Respiratory Health and Multimorbidity, Institute of Respiratory Medicine, Chinese Academy of Medical Sciences, China-Japan Friendship Hospital, Beijing, China.
Yanan CuiDepartment of Pulmonary and Critical Care Medicine, National Center for Respiratory Medicine, State Key Laboratory of Respiratory Health and Multimorbidity, Institute of Respiratory Medicine, Chinese Academy of Medical Sciences, China-Japan Friendship Hospital, Beijing, China.
Tingting HuangDepartment of Pulmonary and Critical Care Medicine, National Center for Respiratory Medicine, State Key Laboratory of Respiratory Health and Multimorbidity, Institute of Respiratory Medicine, Chinese Academy of Medical Sciences, China-Japan Friendship Hospital, Beijing, China.
Xiaoning HeSchool of Pharmaceutical Science and Technology, Tianjin University, Tianjin, China.
Kailing WangSanofi, Shanghai, China.
Dan ShenSanofi, Shanghai, China.
Yingrui XuSanofi, Shanghai, China.
Ting YangDepartment of Pulmonary and Critical Care Medicine, National Center for Respiratory Medicine, State Key Laboratory of Respiratory Health and Multimorbidity, Institute of Respiratory Medicine, Chinese Academy of Medical Sciences, China-Japan Friendship Hospital, Beijing, China. zryyyangting@163.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionDespite receiving triple therapy (i.e., long-acting β

methodsThis retrospective cohort study was conducted using the Chongqing Regional Electronic Health Record Database (2018-2022). Patients with COPD aged ≥ 40 years who had received ≥ 3 months of triple therapy during the 12-month baseline period were included. AER, COPD-related hospital visits, length of hospital stay and readmissions, and direct medical costs during the 12-month observation period were analyzed.

resultsA total of 6393 patients with COPD on triple therapy were included in the study. Among patients with available data, 17.3% had blood eosinophil count of ≥ 300 cell/μL at baseline. The percentage of patients having at least one moderate and severe exacerbation during the observation period was 53.7%, with the moderate and severe AER (95% confidence interval) being 1.37 (1.32-1.42). The mean (standard deviation (SD)) numbers of outpatient, emergency room, and inpatient visit due to COPD were 6.1 (5.56), 0.4 (1.58), and 1.0 (1.64), respectively. The direct medical costs per patient per year were ¥14,208.7.

conclusionOur findings reveal a high disease burden among patients with COPD in China despite stable triple therapy, reflecting the high-risk clinical profile of these patients and supporting an ongoing need for improved management strategies.

Indexed as

Adrenal Cortex HormonesAdrenergic beta-2 Receptor AgonistsMuscarinic AntagonistsPatient Acceptance of Health CarePulmonary Disease, Chronic ObstructiveAdministration, InhalationAgedBronchodilator AgentsChinaDatabases, FactualDisease ProgressionDrug Therapy, CombinationEast Asian PeopleFemaleHealth ResourcesHospitalizationAdrenal Cortex HormonesAdrenergic beta-2 Receptor AgonistsBronchodilator AgentsMuscarinic AntagonistsBlood eosinophil countChronic obstructive pulmonary diseaseExacerbationHealthcare resource utilizationTriple therapy

Identifiers

PMID42159954
PMCPMC13415666

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.